Compare DENTSPLY SIRONA Inc (XRAY) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DENTSPLY SIRONA Inc vs 22nd Century Group Inc — how do they compare? DENTSPLY SIRONA Inc trades at $8.83 (market cap $1.73B), while 22nd Century Group Inc trades at $0.81 (market cap $621.67K). The key difference: DENTSPLY SIRONA Inc is far larger — about 2782.8× 22nd Century Group Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DENTSPLY SIRONA Inc for 72 Days and 22nd Century Group Inc for 32 Days on average.
| XRAY | XXII | |
|---|---|---|
Market Cap | $1.73B | $621.67K |
Volume | 6,198,582 | 45,625 |
Sector | Health | Consumer Staples |
52-Week High | $14.68 | $483.00 |
52-Week Low | $8.52 | $0.80 |
Typical Hold Time | 72 Days | 32 Days |
Enterprise Value | $3.80B | -$3.69M |
Dividend Yield | 5.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DENTSPLY SIRONA (XRAY) trades at $8.69, down 1.76% on the day and near a 52-week low, reflecting ongoing operational challenges. The stock shows a bearish technical trend with weak moving averages, while fundamentals reveal declining revenue, negative net income margins, and elevated debt levels. Recent Q2 2026 earnings beat expectations but sales fell 4.1%, indicating persistent headwinds in dental markets.
The outlook remains cautious due to margin pressure and competitive threats, though analyst consensus suggests upside to a $13.40 price target. Key risks include execution of the turnaround plan, macroeconomic sensitivity, and high leverage. Investment appeal hinges on successful restructuring and recovery in core dental segments.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
